WoS İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6
Browse
2 results
Search Results
Article Post Challenge Effects of Ozg-38.61.3 Gamma Irradiated SARS-CoV Vaccine on Organ Protection in Transgenic Mouse Model(Marmara University, Institute of Health Sciences, 2025) Telci, Dilek; Akpınar, Gürler; Tuğlu, Mehmet İbrahim; Ovalı, Ercüment; Oztatlıcı, Hulya; Şahin, Fikrettin; Demir, Sevda; Kancagi, Derya Dilek; Turan, Raife Dilek; Oztatlici, Mustafa; Karakus, Gozde Sir; Yurtsever, BulutObjective: Coronavirus disease 2019 (COVID-19) is an infectious outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) and virus-related deaths are increasing day by day. For this reason, vaccine studies and their urgent use are of great importance to prevent the pandemic. In this study, multi-organ damages caused by SARS-CoV-2 virus in human- angiotensin-converting enzyme type 2 (ACE2) transgenic mice and the protective effects of OZG-38.61.3 gamma irradiated SARS-CoV-2 vaccine against viral damage were investigated. Methods: For this purpose, transgenic K18-hACE2 BALB/c mice were randomly allocated into 4 groups, negative control group (NC), positive control group (PC, SARS-CoV-2 infected), and 2 different doses of OZG-38.61.3 vaccine (Challenge 1, dose of 10 13 and Ch2, 10 14 viral particle after SARS-CoV-2 infection). After the administrations, lung, heart and kidney tissues were examined by histopathological, immunohistochemical and TUNEL analysis. Results: Our results showed that the vaccine doses decreased the apoptosis, oxidative stress and inflammation parameters caused by virus in lung, heart, and kidney tissues. It was also found that the vaccine protected the expressions of tight junction proteins in the kidneys. Conclusion: According to our findings, it is suggested that the OZG-38.61.3 can be an effective and protective vaccine that can be safely used against the SARS-CoV-2 virus.Article Citation - WoS: 20Citation - Scopus: 20A Multinational Cross-Sectional Study on the Awareness and Concerns of Healthcare Providers Toward Monkeypox and the Promotion of the Monkeypox Vaccination(Frontiers Media Sa, 2023) Swed, Sarya; Alibrahim, Hidar; Bohsas, Haidara; Jawish, Nagham; Rais, Mohammed Amir; Nasif, Mohamad Nour; Data Collection Grp; Elsayed, Mohamed E. G.; Grp, Data CollectionBackgroundThe aim of this study was to explore potential healthcare workers' (HCWs) concerns about the monkeypox virus in order to create practical solutions to manage this disease. MethodsOnline cross-sectional research was conducted in 11 Arabic countries (Egypt, Saudi Arabia, Yemen, Syria, Libya, Algeria, Tunisia, Iraq, Palestine, Jordan, and Sudan) from 2 August 2022 to 28 December 2022. ResultsApproximately 82% of respondents felt the need to acquire further information. The acceptability of the vaccine against monkeypox has been indicated by more than half of the participants (54.5%). Furthermore, we state that 45% of the participants are knowledgeable about the monkeypox virus, and 53.1% of the participants have never been affected with COVID-19 before are more worried about COVID-19 than about monkeypox. Participants diagnosed with COVID-19 were 0.63 times less likely to worry about monkeypox than those who were not diagnosed with COVID-19. A greater willingness to get the monkeypox vaccination was seen among the age group 21-30 years (42.4%) compared to the other age groups. ConclusionMost healthcare professionals have a moderate knowledge of the monkeypox virus. Furthermore, they demonstrated a low willingness to get the vaccination against the monkeypox virus.